Sinocelltech Ltd. clinical trials

A subsidiary of Sinocelltech Group Limited

The registry lists 81 studies whose lead sponsor is Sinocelltech Ltd.. 32 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 81. List all 81 → · All Sinocelltech Group Limited studies →

• A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10Not yet recruitingNCT07847697Phase 1

  Sponsor listed in the registry: Sinocelltech Ltd.

• SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin LymphomaNot yet recruitingNCT07819188Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaRecruitingNCT07562022Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07570823Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid TumorsNot yet recruitingNCT07665970Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerRecruitingNCT07662395Phase 2/3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）Not yet recruitingNCT07609251Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid TumoursNot yet recruitingNCT07594028Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07244510Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Clinica Study of SCTC21C in Participants With Systemic Lupus ErythematosusNot yet recruitingNCT07538154Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.RecruitingNCT07437404Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)RecruitingNCT07388602Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07297329Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.RecruitingNCT07362459Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMDRecruitingNCT06672536Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Phase I/II Study of SCTB39G in Advanced Solid TumoursNot yet recruitingNCT07077252Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Phase I/II Study of SCTB39-1 in Advanced Solid TumoursRecruitingNCT07050641Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study of SCTB35 in Patients with Systemic Lupus ErythematosusRecruitingNCT06841042Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus VaccineRecruitingNCT06754605Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster VaccineNot yet recruitingNCT06801509Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.RecruitingNCT06600022Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.Not yet recruitingNCT06769984Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Clinical Study of SCTC21C in Participants With CD38+ Hematologic MalignanciesRecruitingNCT06252298Phase 1

  Sponsor listed in the registry: Sinocelltech Ltd.

• A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT06318884Phase 1

  Sponsor listed in the registry: Sinocelltech Ltd.

• Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.Not yet recruitingNCT06304818Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Efficacy and Safety of SCT650C in Participants With Axial SpondyloarthritisNot yet recruitingNCT06197009Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster VaccinesNot yet recruitingNCT05933512Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• Evaluate the Safety and Tolerability of SCT650C in Healthy VolunteersNot yet recruitingNCT05894707Phase 1

  Sponsor listed in the registry: Sinocelltech Ltd.

• This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMDRecruitingNCT05480293Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19Not yet recruitingNCT04709328Phase 2/3

  Sponsor listed in the registry: Sinocelltech Ltd.

• Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.RecruitingNCT03947567Phase 4

  Sponsor listed in the registry: Sinocelltech Ltd.

• The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19TerminatedNCT04644185Phase 2/3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 YearsActive, not recruitingNCT05308576Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung CancerTerminatedNCT04171284Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 YearsWithdrawnNCT05308602Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 VaccineWithdrawnNCT05239975Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated AdultsCompletedNCT05148091Phase 1/2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCompletedNCT05652543Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT04560894Phase 2/3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 YearsActive, not recruitingNCT06041061Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster VaccinesStatus unknownNCT05323461Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023Status unknownNCT05758675

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy PeopleStatus unknownNCT05683561Phase 3

  Sponsor listed in the registry: Sinocelltech Ltd.

• SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT05552807Phase 1

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 YearsStatus unknownNCT05522829Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 YearsStatus unknownNCT05345873Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 YearsStatus unknownNCT05329051Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 VaccineStatus unknownNCT05239806Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.

• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 VaccineStatus unknownNCT05238441Phase 2

  Sponsor listed in the registry: Sinocelltech Ltd.